Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation with Weekly vs Every 3 Weeks Cisplatin in Advanced Head and Neck Cancer
NCT05050162Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Feb 2022
- Primary completion
- Feb 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by NRG Oncology. Primary endpoints: Incidence of acute toxicity (Phase II) at 180 days, Overall survival at 9 years and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05050162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050162.